




Infectious  
Diseases Labs

ID LABS

# ID LABS SEMINAR SERIES



## Dr Andrés Pizzorno

Centre International de Recherche en Infectiologie (CIRI)

Team VirPath, France



Wednesday 6<sup>th</sup> October 2021

4pm to 5pm (SGT)

Join zoom meeting [here](#)

Meeting ID: 996 1672 1810

Passcode: 051987



Webinar is open to all  
No registration required

## Decoding and exploiting virus-host interactions to better harness respiratory viral infections

**Dr Andrés Pizzorno** graduated with a B.Sc. in Biochemistry from Universidad de la República (Uruguay) in 2008. His academic research work on respiratory viruses took him to Dr. Guy Boivin's research team at Laval University (Canada), where he obtained his M.Sc. and Ph.D. in Microbiology-Immunology (2011 and 2015), focusing on the mechanisms of antiviral resistance in influenza viruses and the evaluation of new combined therapies. Former fellow of the Knowledge Translation and Pandemic Preparedness Program of the PHAC-CIHR Influenza Research Network (Canada), he works since 2015 as a postdoctoral researcher at the VirPath Team of the Centre International de Recherche en Infectiologie (CIRI) in Lyon (France). Building on +12 years of research experience in the field of respiratory viruses, antiviral resistance and therapeutics, his research focuses on the study of virus-host interactions at the transcriptomic, molecular and cellular level, with particular attention on the interplay between the virus and the early innate immune response as the starting point for the identification, characterization, pre-clinical and clinical evaluation of innovative host-targeted antiviral approaches. The scientific expertise of Dr. Pizzorno is mainly centered on the fields of virology, immunology, lung physiology, reverse-genetics, antiviral evaluation and novel in vitro/in vivo models. He is author of 40 scientific publications and co-inventor of several patents, and leads/participates in different collaborative research projects at the national (France) and international level, including the French REACTing network (<https://reacting.inserm.fr/>) for the national response to the SARS-CoV-2 virus pandemic outbreak. Since 2017, Dr. Pizzorno is also co-founder of Signia Therapeutics SAS, an innovative company based on a breakthrough proprietary drug-discovery strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to "rediscover" unused drugs for new antimicrobial indications against several human pathogens. Twitter: @PizzornoAndres